503B Outsourcing Facility
An FDA-registered facility that compounds medications in bulk without patient-specific prescriptions, subject to current good manufacturing practice standards.
A 503B outsourcing facility is registered with the FDA under Section 503B of the Federal Food, Drug, and Cosmetic Act. Unlike 503A pharmacies, 503B facilities can produce large batches of compounded medications without a patient-specific prescription. They are held to cGMP standards and undergo regular FDA inspections, which generally means tighter quality controls and greater batch consistency.
For clinic operators, 503B facilities offer volume advantages. You can pre-position inventory and fulfill orders faster because the pharmacy is not waiting on a per-patient prescription to begin compounding. This matters for high-volume GLP-1 or peptide programs where patient throughput is significant.
The tradeoff is that 503B compounding is more narrowly permitted by the FDA. The agency maintains a list of bulk drug substances eligible for 503B compounding. Operators should verify their formulary against the current FDA list and work with compliance counsel when building a high-volume fulfillment strategy.
Related Terms
Frequently Asked Questions
Can I use a 503B facility for a GLP-1 program? expand_more
How does 503B differ from 503A for a telehealth operator? expand_more
Does Karpa work with 503B facilities? expand_more
Ready to launch your clinic?
Karpa provides everything you need to go live in 2 weeks or less.
Book a Free Demo